Views & Analysis Disruptive innovation, integrated care the only way forward,... Peter Guenter, head of Sanofi’s Diabetes & Cardiovascular business, on the future of chronic disease care.
News Sanofi/Regeneron eczema data paves way for year's biggest la... Companies look to take on Pfizer after series of setbacks.
News After missing out on CEO job, Novo's US head quits The pressure on Novo Nordisk's diabetes portfolio is mounting in the US - and the situation seems even more precarious after its top exec in the region quit.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.